Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

NCT01310803 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma in Situ
Transitional Cell Carcinoma
Non-muscle Invasive Bladder Cancer

Interventions

DRUG: VALSTAR - Maintenance Therapy
OTHER: No Maintenance treatment ( Standard of Care)

Sponsor

Endo Pharmaceuticals